Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
Total Valuation
Arrowhead Pharmaceuticals has a market cap or net worth of $2.17B. The enterprise value is $3.46B.
Market Cap$2.17B
Enterprise Value$3.46B
Share Statistics
Arrowhead Pharmaceuticals has 138,100,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,100,430
Owned by Insiders4.24%
Owned by Institutions21.20%
Financial Efficiency
Arrowhead Pharmaceuticals’s return on equity (ROE) is -3.23 and return on invested capital (ROIC) is -57.37%.
Return on Equity (ROE)-3.23
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-57.37%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee5.83K
Profits Per Employee-1.00M
Employee Count609
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arrowhead Pharmaceuticals is -3.87. Arrowhead Pharmaceuticals’s PEG ratio is -0.87.
PE Ratio-3.87
PS Ratio0.00
PB Ratio32.88
Price to Fair Value12.51
Price to FCF-18.44
Price to Operating Cash Flow-25.60
PEG Ratio-0.87
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M and earned -599.49M in profits. Earnings per share was -5.00.
Revenue3.55M
Gross Profit3.55M
Operating Income-601.08M
Pretax Income-612.46M
Net Income-599.49M
EBITDA-561.51M
Earnings Per Share (EPS)-5.00
Cash Flow
In the last 12 months, operating cash flow was -491.28M and capital expenditures -80.33M, giving a free cash flow of -571.61M billion.
Operating Cash Flow-491.28M
Free Cash Flow-571.61M
Free Cash Flow per Share-4.14
Dividends & Yields
Arrowhead Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.35
52-Week Price Change-34.85%
50-Day Moving Average14.32
200-Day Moving Average18.20
Relative Strength Index (RSI)48.22
Average Volume (3m)1.70M
Important Dates
Arrowhead Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Arrowhead Pharmaceuticals as a current ratio of 6.74, with Debt / Equity ratio of 76.99%
Current Ratio6.74
Quick Ratio6.74
Debt to Market Cap0.17
Net Debt to EBITDA-0.73
Interest Coverage Ratio-18.58
Taxes
In the past 12 months, Arrowhead Pharmaceuticals has paid -2.77M in taxes.
Income Tax-2.77M
Effective Tax Rate<0.01
Enterprise Valuation
Arrowhead Pharmaceuticals EV to EBITDA ratio is -4.86, with an EV/FCF ratio of -4.51.
EV to Sales768.26
EV to EBITDA-4.86
EV to Free Cash Flow-4.51
EV to Operating Cash Flow-5.89
Balance Sheet
Arrowhead Pharmaceuticals has $552.93M in cash and marketable securities with $525.27M in debt, giving a net cash position of -$27.66M billion.
Cash & Marketable Securities$552.93M
Total Debt$525.27M
Net Cash-$27.66M
Net Cash Per Share-$0.20
Tangible Book Value Per Share$1.52
Margins
Gross margin is 95.72%, with operating margin of -16927.06%, and net profit margin of -16882.37%.
Gross Margin95.72%
Operating Margin-16927.06%
Pretax Margin-17247.54%
Net Profit Margin-16882.37%
EBITDA Margin-15812.81%
EBIT Margin-16336.47%
Analyst Forecast
The average price target for Arrowhead Pharmaceuticals is $41.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.00
Price Target Upside164.52% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast1436.97%
EPS Growth Forecast68.03%